Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

TP53 outperforms other androgen receptor biomarkers to predict abiraterone or enzalutamide outcome in metastatic castration-resistant prostate cancer.

De Laere B, Oeyen S, Mayrhofer M, Whitington T, van Dam PJ, Van Oyen P, Ghysel C, Ampe J, Ost P, Demey W, Hoekx L, Schrijvers D, Brouwers B, Lybaert W, Everaert EG, De Maeseneer D, Strijbos M, Bols A, Fransis K, Beije N, de Kruijff IE, van Dam V, Brouwer A, Goossens D, Heyrman L, Van den Eynden GG, Rutten A, Del Favero J, Rantalainen M, Rajan P, Sleijfer S, Ullén A, Yachnin J, Grönberg H, Van Laere SJ, Lindberg J, Dirix LY.

Clin Cancer Res. 2018 Sep 12. pii: clincanres.1943.2018. doi: 10.1158/1078-0432.CCR-18-1943. [Epub ahead of print]

PMID:
30209161
2.

Circulating tumor cells and survival in abiraterone- and enzalutamide-treated patients with castration-resistant prostate cancer.

De Laere B, Oeyen S, Van Oyen P, Ghysel C, Ampe J, Ost P, Demey W, Hoekx L, Schrijvers D, Brouwers B, Lybaert W, Everaert E, Van Kerckhove P, De Maeseneer D, Strijbos M, Bols A, Fransis K, Beije N, de Kruijff I, van Dam V, Brouwer A, van Dam PJ, Van den Eynden G, Rutten A, Sleijfer S, Vandebroek J, Van Laere S, Dirix L.

Prostate. 2018 May;78(6):435-445. doi: 10.1002/pros.23488. Epub 2018 Feb 12.

PMID:
29431193
3.

A phase II study of antibody-drug conjugate, TAK-264 (MLN0264) in previously treated patients with advanced or metastatic pancreatic adenocarcinoma expressing guanylyl cyclase C.

Almhanna K, Wright D, Mercade TM, Van Laethem JL, Gracian AC, Guillen-Ponce C, Faris J, Lopez CM, Hubner RA, Bendell J, Bols A, Feliu J, Starling N, Enzinger P, Mahalingham D, Messersmith W, Yang H, Fasanmade A, Danaee H, Kalebic T.

Invest New Drugs. 2017 Oct;35(5):634-641. doi: 10.1007/s10637-017-0473-9. Epub 2017 May 19.

PMID:
28527133
4.

Systematic review and meta-analysis of local resection or transanal endoscopic microsurgery versus radical resection in stage i rectal cancer: A real standard?

Veereman G, Vlayen J, Robays J, Fairon N, Stordeur S, Rolfo C, Bielen D, Bols A, Demetter P, D'hoore A, Haustermans K, Hendlisz A, Lemmers A, Leonard D, Penninckx F, Van Cutsem E, Peeters M.

Crit Rev Oncol Hematol. 2017 Jun;114:43-52. doi: 10.1016/j.critrevonc.2017.03.008. Epub 2017 Apr 1. Review.

PMID:
28477746
5.

Hemoglobin levels and quality of life in patients with symptomatic chemotherapy-induced anemia: the eAQUA study.

Mouysset JL, Freier B, van den Bosch J, Levaché CB, Bols A, Tessen HW, Belton L, Bohac GC, Terwey JH, Tonini G.

Cancer Manag Res. 2016 Jan 21;8:1-10. doi: 10.2147/CMAR.S88110. eCollection 2016.

6.

Prospective non-interventional multicentre observational trial of first-line anti-cancer treatment in patients with metastatic renal cell cancer in Belgium.

Cornelis N, Vermassen T, Schallier D, Machiels JP, Gil T, Debruyne PR, D'hondt R, Bols A, Schrijvers D, Mebis J, Lumen N, Rottey S.

Acta Clin Belg. 2014 Oct;69(5):335-40. doi: 10.1179/2295333714Y.0000000051. Epub 2014 Jul 24.

PMID:
25056491
7.

Model-based iterative reconstruction and adaptive statistical iterative reconstruction techniques in abdominal CT: comparison of image quality in the detection of colorectal liver metastases.

Volders D, Bols A, Haspeslagh M, Coenegrachts K.

Radiology. 2013 Nov;269(2):469-74. doi: 10.1148/radiol.13130002. Epub 2013 Jul 11.

PMID:
23847252
8.

Prediction and monitoring of treatment effect using T1-weighted dynamic contrast-enhanced magnetic resonance imaging in colorectal liver metastases: potential of whole tumour ROI and selective ROI analysis.

Coenegrachts K, Bols A, Haspeslagh M, Rigauts H.

Eur J Radiol. 2012 Dec;81(12):3870-6. doi: 10.1016/j.ejrad.2012.07.022. Epub 2012 Sep 1.

PMID:
22944331
9.

Prevalence of BRCA1/2 mutations in sporadic breast/ovarian cancer patients and identification of a novel de novo BRCA1 mutation in a patient diagnosed with late onset breast and ovarian cancer: implications for genetic testing.

De Leeneer K, Coene I, Crombez B, Simkens J, Van den Broecke R, Bols A, Stragier B, Vanhoutte I, De Paepe A, Poppe B, Claes K.

Breast Cancer Res Treat. 2012 Feb;132(1):87-95. doi: 10.1007/s10549-011-1544-9. Epub 2011 May 7.

PMID:
21553119
10.

Epoetin alfa improves anemia and anemia-related, patient-reported outcomes in patients with breast cancer receiving myelotoxic chemotherapy: results of a European, multicenter, randomized, controlled trial.

Pronzato P, Cortesi E, van der Rijt CC, Bols A, Moreno-Nogueira JA, de Oliveira CF, Barrett-Lee P, Ostler PJ, Rosso R; EPO-INT-47 Study Group.

Oncologist. 2010;15(9):935-43. doi: 10.1634/theoncologist.2009-0279. Epub 2010 Aug 26.

11.

Epidermal growth factor receptor and K-RAS status in two cohorts of squamous cell carcinomas.

Van Damme N, Deron P, Van Roy N, Demetter P, Bols A, Van Dorpe J, Baert F, Van Laethem JL, Speleman F, Pauwels P, Peeters M.

BMC Cancer. 2010 May 11;10:189. doi: 10.1186/1471-2407-10-189.

12.

Fulvestrant (Faslodex) in advanced breast cancer: clinical experience from a Belgian cooperative study.

Neven P, Paridaens R, Pelgrims G, Martens M, Bols A, Goeminne JC, Vindevoghel A, Demol J, Stragier B, De Greve J, Fontaine C, Van Den Weyngaert D, Becquart D, Borms M, Cocquyt V, Van Den Broecke R, Selleslags J, Awada A, Dirix L, Van Dam P, Azerad MA, Vandenhoven G, Christiaens MR, Vergote I.

Breast Cancer Res Treat. 2008 May;109(1):59-65. Epub 2007 Jun 26.

PMID:
17592772
13.

Recurrent bacteremia by Chryseobacterium indologenes in an oncology patient with a totally implanted intravascular device.

Nulens E, Bussels B, Bols A, Gordts B, Van Landuyt HW.

Clin Microbiol Infect. 2001 Jul;7(7):391-3.

14.

Atheromatous embolization precipitated by oral anticoagulants.

Bols A, Nevelsteen A, Verhaeghe R.

Int Angiol. 1994 Sep;13(3):271-4.

PMID:
7822905
15.

Recurrent meningococcal infections in a patient with congenital C5 deficiency.

Bols A, Janssens J, Peetermans W, Stevens E, Bobbaers H.

Acta Clin Belg. 1993;48(1):42-7.

PMID:
8388602

Supplemental Content

Support Center